Meeting
2021 ASCO Annual Meeting
Winship 4851-19: A pilot study of neoadjuvant and adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma.
Authors
Michael C. Lowe
Department of Surgery, Emory University, Atlanta, GA
Michael C. Lowe , Melinda Lynne Yushak , Keith A. Delman , Monica Rizzo , Caroline Claar , Allyson Schmidt , Jeffrey M. Switchenko , David H. Lawson , Ragini Reiney Kudchadkar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT04428671
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9593)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9593
Abstract #
TPS9593
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
NEO-CESQ study: Neoadjuvant plus adjuvant treatment with cemiplimab in surgically resectable, high risk stage III/IV (M0) cutaneous squamous cell carcinoma.
First Author: Paolo Antonio Ascierto
Poster
2023 ASCO Annual Meeting
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.
First Author: Maria Gonzalez
Poster
2020 ASCO Virtual Scientific Program
A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
First Author: Danny Rischin
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%.
First Author: Neil E. Faulkner